| European biopharmaceutical manufacturers and contract manufacturing
organisations (CMOs) are planning for significant capacity expansions, as much
as 66 per cent for some systems, by 2012. Some areas of projected capacity
increases in European biomanufacturing and contract manufacturing could
outstrip US expansions by 30 per cent over the next four years.
These data, from the 5th Annual Report
and Survey of Biopharmaceutical
Manufacturing (1), are among many issues
probed through an annual global study of
434 industry biomanufacturers and CMOs.
One of the major findings was the fiveyear
capacity expansion trend comparisons
between US and Western European
biomanufacturers.
To put the data in context, the annual
report provides a composite view and
trend analysis from biopharmaceutical
manufacturers and contract manufacturing
organisations in 32 countries. It covers
manufacturing issues including: current
capacity, future capacity constraints,
expansions, use of disposables, trends
and budgets in disposables, trends
in downstream purification, quality
management and control, hiring issues,
employment and training.
PLANNED FUTURE CAPACITY
EXPANSIONS: 2012
Survey respondents were asked to
indicate how much their facility will
increase production capacity overall by
2012. Figure 1 shows average projected
capacity expansion from 2008 to
2012, and compares responses from
Western European and US-based
biomanufacturers and CMOs. |
